Dr. Yu Chen 陈誉
Chief Physician, Associate Professor
Medical Oncology, Fujian Cancer Hospital, Fuzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy, molecular targeted therapy, and immunotherapy for melanoma, urologic, soft tissue, and digestive system malignancies, with a focus on tumor immunotherapy.
Dr. Chen holds a PhD in Oncology and completed postdoctoral training at Shanghai Jiao Tong University. As Chief Physician and Associate Professor, Dr. Chen leads the Melanoma MDT group and the Internal Medicine Teaching Department at Fujian Cancer Hospital. Research includes National Natural Science Foundation projects. Dr. Chen has published 45 SCI papers and presented findings at ASCO, ESMO, and SITC conferences.
Professional roles
- Standing Committee Member, Melanoma Expert Committee, Chinese Society of Clinical Oncology (CSCO)
- Member, Urothelial Carcinoma Expert Committee, CSCO
- Member, Medical Oncology Expert Committee, Oncology Branch, Chinese Medical Association
- Chair, Melanoma Professional Committee, Fujian Anti-Cancer Association
Name order: in Chinese the family name comes first (Chen Yu). Papers usually list the name as Yu Chen or Chen Y.
Selected publications
131 papers on PubMed matched by name and affiliation; 28 as first or senior author since 2016. Most recent first- or senior-author papers:
- Br J Dermatol, 2026 (senior author): Lifetime risk of cutaneous melanoma in 185 countries: decomposing its difference from cumulative risk into methodological and longevity effects. PubMed 42598772
- Mol Cancer, 2026 (senior author): Spatial proteomics reveals four-stage molecular evolution in cancer immunotherapy-related gastritis. PubMed 42482033
- MedComm (2020), 2026 (senior author): Efficacy and Safety of DNV3 (a Lymphocyte-activation Gene 3-blocking Antibody) Combined With Toripalimab and Chemotherapy in Advanced Melanoma: An Open-label, Single-arm Clinical Trial. PubMed 41782961
- Biochem Pharmacol, 2026 (senior author): Current status and prospects of methylthioadenosine phosphorylase/protein arginine methyltransferase 5 target therapy. PubMed 41314432
- Mol Biotechnol, 2025 (senior author): Prognostic and Potential Therapeutic Roles of PRKDC Expression in Lung Cancer. PubMed 39044064
- J Inflamm Res, 2025 (senior author): DNA-PKcs Dysfunction Enhances the Antitumor Activity of Radioimmunotherapy by Activating the cGAS-STING Pathway in HNSCC. PubMed 40129873
- Front Immunol, 2024 (senior author): Tocilizumab in combination with corticosteroids: potential for managing cancer cachexia with systemic hyperinflammation. PubMed 39703501
- BMC Cancer, 2024 (senior author): MET amplification correlates with poor prognosis and immunotherapy response as a subtype of melanoma: a multicenter retrospective study. PubMed 39528978
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion